

Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline

Guideline Name	Austedo (deutetrabenazine)
-----------------------	----------------------------

1. Criteria

Product Name: Austedo	
Diagnosis	Chorea associated with Huntington's Disease
Approval Length	12 Month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
Approval Criteria	
1 - Diagnosis of chorea associated with Huntington's disease	

Product Name: Austedo	
Diagnosis	Tardive Dyskinesia
Approval Length	12 Month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization
Approval Criteria	
1 - Diagnosis of tardive dyskinesia	
AND	
2 - Patient is 18 years of age or older	
AND	
3 - Prescribed by or in consultation with ONE of the following:	
<ul style="list-style-type: none"> • Neurologist; OR • Psychiatrist 	
AND	
4 - Patient has experienced symptoms of tardive dyskinesia for at least 8 weeks	

Product Name: Austedo	
Diagnosis	All indications
Approval Length	12 Month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization
Approval Criteria	
1 - Patient has experienced improvement while on Austedo therapy	

2. Background

Benefit/Coverage/Program Information		
RATIONALE		
To promote the first line use of preferred, formulary agents for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.		
FDA APPROVED INDICATIONS		
Austedo (deutetrabenazine) is indicated for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults.		
DOSING	Austedo (6 mg, 9 mg, 12 mg tablets)	
	Initial Dose	Maintenance Dose
Chorea associated with Huntington's disease	6 mg/day	6 mg – 48 mg/day
Tardive dyskinesia	12 mg/day	12 mg – 48 mg/day
REFERENCES		
<ul style="list-style-type: none"> • Austedo (deutetrabenazine) [prescribing information]. Teva Pharmaceuticals; North Wales, PA: February 2020. • Summary of Evidence-based Guideline for Clinicians: Treatment of Tardive Syndromes. American Academy of Neurology 2013; reaffirmed July 2016. Available at www.AAN.com/Guidelines. • Meyer TA, Belson TE, McAllister R. Tardive Dyskinesia: A Distressing Drug-Induced Movement Disorder. U.S. Pharmacist 2014; 39(1):HS13-HS16. • Sucherowersky, O. Huntington Disease: Management. In: UpToDate, Dashe, J (ed), Waltham, MA. Sept 2017. • Tarsy, D. Tardive Dyskinesia: Prevention and Treatment. In: UpToDate, Dashe, J (ed), Waltham, MA. Sept 2017. • Xenazine (tetrabenazine) [prescribing information]. Lundbeck Pharmaceuticals LLC; Deerfield, IL: September 2017. 		
Created: 07/18		
Revised:		
<ul style="list-style-type: none"> • Annual review (effective: 1/1/20) • 10/29/20 - Annual review: background changes; no criteria changes 		
P&T Approval: 12/7/20		
Effective: 1/1/21		